Impact of GLP-1 Medications on Oral Health in Sleep Apnea Treatment

Medications such as tirzepatide and semaglutide are transforming the management of obesity, diabetes, and obstructive sleep apnea (OSA). A researcher from the Dental College of Georgia is investigating an area that has not received significant attention: the potential implications of these medications for oral health.

The oral microbiome, which consists of various bacteria essential for maintaining healthy teeth and gums, can be disrupted by OSA. Factors such as repeated drops in oxygen levels, inflammation, mouth breathing, and dry mouth contribute to this imbalance. Additionally, fluctuations in blood sugar and acid reflux linked with OSA may further impact the oral environment.

“OSA affects much more than sleep,” said Comisi. “The changes occurring in the body can alter the mouth’s environment. As we increasingly utilize medications to treat OSA, it’s crucial to understand their effects on oral health.”

In December 2024, the U.S. Food and Drug Administration approved tirzepatide for adults with moderate-to-severe OSA and obesity. Clinical trials indicated that this medication reduced the frequency of sleep interruptions and helped some participants achieve remission of OSA.

Comisi’s review implies that treating OSA could enhance the oral environment by decreasing factors like mouth breathing and acid reflux that negatively impact oral health. However, GLP-1 medications may also influence saliva production. While reports on semaglutide noted dry mouth and potential changes in saliva, these findings do not establish a clear cause or frequency. This raises a critical question: could the oral health benefits of treating OSA be diminished by medication-related changes in saliva?

“There are potentially competing effects happening at the same time,” Comisi explained. “While treating sleep apnea may improve conditions detrimental to oral health, the medication itself could alter salivary function. Current research lacks prospective human studies to clarify the overall impact.”

To date, no prospective human study has monitored patients with OSA starting GLP-1 therapy while assessing their oral microbiome. Comisi emphasizes the need for dentists to monitor saliva production, cavities, and gum health as patients initiate treatment.

The review advocates for collaboration among dentists, sleep specialists, and medical researchers. Future investigations could examine changes in saliva, oral bacteria, cavities, and gum disease over one to two years.

GLP-1 medications can also slow gastric emptying, which is important when planning dental procedures involving sedation or general anesthesia. Comisi notes that further research is essential to determine the full effects of these medications on oral health.

“GLP-1 therapy is rapidly becoming integrated into the treatment regimen for sleep apnea,” Comisi stated. “This provides an opportunity for dentistry to be included in the discussion early on. Understanding how these medications influence the mouth is vital to identifying potential issues promptly and ensuring comprehensive patient care.”